CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
20.43
1.4%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Thu: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.12
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Denali Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 20.72
Open* 20.58
1-Year Change* -11.45%
Day's Range* 20.06 - 20.95
52 wk Range 15.45-33.31
Average Volume (10 days) 1.04M
Average Volume (3 months) 21.52M
Market Cap 2.31B
P/E Ratio -100.00K
Shares Outstanding 138.20M
Revenue 340.81M
EPS -0.97
Dividend (Yield %) N/A
Beta 1.32
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 20.43 -0.29 -1.40% 20.72 20.98 20.06
Mar 27, 2024 20.72 0.89 4.49% 19.83 20.86 19.75
Mar 26, 2024 19.81 -0.17 -0.85% 19.98 20.11 19.40
Mar 25, 2024 19.80 0.53 2.75% 19.27 19.88 19.27
Mar 22, 2024 19.55 -1.28 -6.14% 20.83 20.93 19.51
Mar 21, 2024 20.92 -0.33 -1.55% 21.25 21.36 20.87
Mar 20, 2024 21.22 1.43 7.23% 19.79 21.42 19.79
Mar 19, 2024 20.48 0.76 3.85% 19.72 20.58 19.72
Mar 18, 2024 20.06 0.08 0.40% 19.98 20.53 19.74
Mar 15, 2024 20.09 0.48 2.45% 19.61 20.28 19.59
Mar 14, 2024 19.70 -0.84 -4.09% 20.54 20.61 19.19
Mar 13, 2024 20.84 0.36 1.76% 20.48 21.30 20.45
Mar 12, 2024 20.71 -0.72 -3.36% 21.43 21.55 20.55
Mar 11, 2024 21.65 0.80 3.84% 20.85 21.79 20.80
Mar 8, 2024 20.87 0.25 1.21% 20.62 21.60 20.62
Mar 7, 2024 20.47 -0.04 -0.20% 20.51 20.68 20.28
Mar 6, 2024 20.45 -0.15 -0.73% 20.60 21.00 20.23
Mar 5, 2024 20.38 -0.05 -0.24% 20.43 21.13 19.90
Mar 4, 2024 20.60 -0.37 -1.76% 20.97 21.35 20.43
Mar 1, 2024 20.82 0.91 4.57% 19.91 21.38 19.69

Denali Therapeutics Events

Time (UTC) Country Event
Monday, May 6, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Denali Therapeutics Inc Earnings Release
Q1 2024 Denali Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Friday, May 31, 2024

Time (UTC)

17:00

Country

US

Event

Denali Therapeutics Inc Annual Shareholders Meeting
Denali Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 108.463 48.661 335.659 26.678 129.16
Total Operating Expense 449.207 344.412 272.941 239.862 175.532
Selling/General/Admin. Expenses, Total 90.475 79.059 60.326 46.48 32.349
Research & Development 358.732 265.353 212.615 193.382 143.183
Operating Income -340.744 -295.751 62.718 -213.184 -46.372
Interest Income (Expense), Net Non-Operating 14.774 4.595 9.241 15.219 10.132
Net Income Before Taxes -325.97 -291.156 71.959 -197.965 -36.24
Net Income After Taxes -325.991 -290.581 71.136 -197.614 -36.24
Net Income Before Extra. Items -325.991 -290.581 71.136 -197.614 -36.24
Net Income -325.991 -290.581 71.136 -197.614 -36.24
Income Available to Common Excl. Extra. Items -325.991 -290.581 71.136 -197.614 -36.24
Income Available to Common Incl. Extra. Items -325.991 -290.581 71.136 -197.614 -36.24
Dilution Adjustment
Diluted Net Income -325.991 -290.581 71.136 -197.614 -36.24
Diluted Weighted Average Shares 125.531 121.525 112.703 95.6082 92.622
Diluted EPS Excluding Extraordinary Items -2.5969 -2.39113 0.63118 -2.06691 -0.39127
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -2.5969 -2.39113 0.63118 -2.06691 -0.39127
Revenue 108.463 48.661 335.659 26.678 129.16
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 294.123 35.141 10.283 3.559 52.48
Revenue 294.123 35.141 10.283 3.559 52.48
Total Operating Expense 123.64 155.956 115.627 111.045 113.896
Selling/General/Admin. Expenses, Total 26.12 27.14 23.516 23.259 21.159
Research & Development 97.52 128.816 92.111 87.786 92.737
Operating Income 170.483 -120.815 -105.344 -107.486 -61.416
Interest Income (Expense), Net Non-Operating 12.9 11.034 6.66 4.187 2.649
Net Income Before Taxes 183.383 -109.781 -98.684 -103.299 -58.767
Net Income After Taxes 183.383 -109.781 -98.678 -103.299 -58.794
Net Income Before Extra. Items 183.383 -109.781 -98.678 -103.299 -58.794
Net Income 183.383 -109.781 -98.678 -103.299 -58.794
Income Available to Common Excl. Extra. Items 183.383 -109.781 -98.678 -103.299 -58.794
Income Available to Common Incl. Extra. Items 183.383 -109.781 -98.678 -103.299 -58.794
Diluted Net Income 183.383 -109.781 -98.678 -103.299 -58.794
Diluted Weighted Average Shares 140.931 136.525 132.958 123.473 123.009
Diluted EPS Excluding Extraordinary Items 1.30123 -0.80411 -0.74217 -0.83661 -0.47797
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 1.30123 -0.80411 -0.74217 -0.83661 -0.47797
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1372.32 897.234 1495.66 430.031 480.836
Cash and Short Term Investments 1336.21 865.407 1469.7 415.356 464.297
Cash & Equivalents 218.044 293.477 507.144 79.449 77.123
Short Term Investments 1118.17 571.93 962.553 335.907 387.174
Total Receivables, Net 0 1.226 5.674 1.182
Accounts Receivable - Trade, Net 1.182
Prepaid Expenses 36.104 30.601 20.284 14.675 15.357
Total Assets 1460.24 1404.16 1604.28 553.231 661.984
Property/Plant/Equipment, Total - Net 74.524 69.608 73.464 80.655 25.162
Property/Plant/Equipment, Total - Gross 111.739 98.952 94.266 92.928 37.172
Accumulated Depreciation, Total -37.215 -29.344 -20.802 -12.273 -12.01
Long Term Investments 0 425.449 32.699 39.886 147.881
Other Long Term Assets, Total 13.399 11.871 2.462 2.659 8.105
Total Current Liabilities 363.922 378.245 71.699 45.344 32.786
Accounts Payable 2.79 4.779 1.071 2.59 1.891
Accrued Expenses 66.691 53.165 47.145 24.007 18.472
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 294.441 320.301 23.483 18.747 12.423
Total Liabilities 417.812 441.871 453.749 158.341 115.139
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 53.89 63.626 382.05 112.997 82.353
Total Equity 1042.43 962.291 1150.53 394.89 546.845
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 1.686 1.548 1.531 1.288 1.273
Additional Paid-In Capital 2018.62 1608.24 1503.66 818.803 774.158
Retained Earnings (Accumulated Deficit) -970.987 -644.996 -354.415 -425.551 -227.937
Other Equity, Total -6.886 -2.499 -0.245 0.35 -0.649
Total Liabilities & Shareholders’ Equity 1460.24 1404.16 1604.28 553.231 661.984
Total Common Shares Outstanding 135.966 122.283 120.531 96.1899 94.6624
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 1142.88 1224.06 1325.16 1372.32 1138.53
Cash and Short Term Investments 1107.66 1190.99 1288.45 1336.21 1106.06
Cash & Equivalents 146.411 131.973 68.131 218.044 118.615
Short Term Investments 961.245 1059.01 1220.32 1118.17 987.44
Total Receivables, Net 0 0
Prepaid Expenses 33.628 33.075 36.709 36.104 32.471
Total Assets 1236.78 1305.73 1409.34 1460.24 1227.61
Property/Plant/Equipment, Total - Net 74.851 67.238 70.166 74.524 72.963
Long Term Investments 7.905 0 0
Other Long Term Assets, Total 11.137 14.434 14.016 13.399 16.117
Total Current Liabilities 71.18 69.357 391.08 363.922 360.67
Accounts Payable 1.182 8.52 2.215 2.79 7.539
Accrued Expenses 59.644 53.016 90.57 66.691 61.149
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 10.354 7.821 298.295 294.441 291.982
Total Liabilities 118.446 118.909 442.638 417.812 416.303
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 47.266 49.552 51.558 53.89 55.633
Total Equity 1118.33 1186.82 966.706 1042.43 811.303
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 1.707 1.7 1.694 1.686 1.564
Additional Paid-In Capital 2114.01 2083.95 2048.3 2018.62 1693.9
Retained Earnings (Accumulated Deficit) -996.738 -897.385 -1080.77 -970.987 -872.309
Other Equity, Total -0.651 -1.441 -2.517 -6.886 -11.853
Total Liabilities & Shareholders’ Equity 1236.78 1305.73 1409.34 1460.24 1227.61
Total Common Shares Outstanding 138.052 137.363 136.742 135.966 123.796
Other Current Assets, Total 1.6
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -325.991 -290.581 71.136 -197.614 -36.24
Cash From Operating Activities -244.716 -211.389 416.152 -151.576 50.116
Cash From Operating Activities 10.383 8.593 8.531 7.991 7.415
Non-Cash Items 94.922 93.995 50.444 33.872 16.05
Changes in Working Capital -24.03 -23.396 286.041 4.175 62.891
Cash From Investing Activities -141.387 -21.626 -623.206 147.712 -287.422
Capital Expenditures -17.833 -8.5 -3.095 -17.919 -3.393
Other Investing Cash Flow Items, Total -123.554 -13.126 -620.111 165.631 -284.029
Cash From Financing Activities 310.67 19.348 634.749 6.19 97.019
Financing Cash Flow Items 0 -1.386
Issuance (Retirement) of Stock, Net 310.67 19.348 634.749 6.19 98.405
Net Change in Cash -75.433 -213.667 427.695 2.326 -140.287
Issuance (Retirement) of Debt, Net
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -109.781 -325.991 -227.313 -124.014 -65.22
Cash From Operating Activities -58.802 -244.716 -172.053 -115.007 -72.109
Cash From Operating Activities 10.047 10.383 6.292 4.151 2.079
Non-Cash Items 19.354 94.922 73.653 50.581 26.989
Changes in Working Capital 21.578 -24.03 -24.685 -45.725 -35.957
Cash From Investing Activities -92.715 -141.387 -13.828 -29.247 -117.878
Capital Expenditures -2.786 -17.833 -12.984 -6.934 -4.041
Other Investing Cash Flow Items, Total -89.929 -123.554 -0.844 -22.313 -113.837
Cash From Financing Activities 1.604 310.67 11.019 5.865 1.463
Issuance (Retirement) of Stock, Net 1.604 310.67 11.019 5.865 1.463
Net Change in Cash -149.913 -75.433 -174.862 -138.389 -188.524

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Denali Therapeutics Company profile

About Denali Therapeutics Inc

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase (ETV:IDS) program, receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program and second non-CNS penetrant RIPK1 inhibitor. The Company engineers its product candidates to cross the blood-brain barrier (BBB), and act directly in the brain. Its pipeline includes approximately 15 programs that are based on its TV technology, including the lead program ETV:IDS (DNL310). Its product pipeline includes DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL788, DNL343, DNL758,

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Denali Therapeutics Inc revenues decreased 86% to $48.7M. Net loss totaled $290.6M vs. income of $71.1M. Revenues reflect Other collaboration revenue decrease of 96% to $4K. Net loss reflects Research & Development Expense - Balanci increase of 17% to $215.3M (expense), Stock-based Compensation in R&D increase of 73% to $50M (expense).

Industry: Bio Therapeutic Drugs

161 Oyster Point Blvd
SOUTH SAN FRANCISCO
CALIFORNIA 94080-1910
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

XRP/USD

0.62 Price
-1.590% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

70,126.15 Price
-0.570% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading